Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have low or intermediate risk adenocarcinoma of the prostate as defined by:~  * Low-risk disease - Histopathology score (Gleason sum): =\<6, T-stage (per current AJCC staging criteria): T1c-T2a, and PSA: \<10~ * Intermediate-risk disease as either:~    * Histopathology score (Gleason sum) =\< 6, T-stage (per current American Joint Committee on Cancer \[AJCC\] staging criteria): T1c-T2a, and prostate-specific antigen (PSA) \> 10 but =\< 20; or~   * Histopathology score (Gleason sum) 7 with =\< 50% of any cores positive, T-stage (per current AJCC staging criteria): T1c-T2a, and PSA \< 10~* Charlson index of comorbidity score =\< 4~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Patients with history of inflammatory bowel disease, or who require steroid or cytotoxic therapy for collagen vascular disease~* Patients with a history of cancer other than skin cancer within 5 years of the initiation of protocol treatment~* Patients with a history of pelvic irradiation for any reason~* Life expectancy \< 10 years - Prior treatment with an anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist, or a combination of the two~* Prior radiation therapy, brachytherapy, or cryotherapy~* Prior surgical procedure involving peri-rectal and peri-prostatic area

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (standard stereotactic body radiation therapy (SBRT) (Type: ACTIVE_COMPARATOR): Patients undergo standard daily fractions of SBRT over 7-8.5 weeks
- Arm II (four fraction split-course SBRT) (Type: EXPERIMENTAL): Patients undergo 2 fractions of SBRT in weeks 1 and 4

Based on this trial design, predict the completion outcome and termination type (if applicable).